3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Melanoma
23
Multiple Myeloma
9
Colorectal Neoplasms
9
Carcinoma, Non-Small-Cell Lung
9
Glioma
8
Thyroid Neoplasms
7
Neoplasm Metastasis
7
Hematologic Neoplasms
6
Thyroid Carcinoma, Anaplastic
5
Lymphoma
5
Thyroid Cancer, Papillary
4
Pancreatic Neoplasms
4
Neurofibromatosis 1
4
Neoplasms
4
Lung Neoplasms
3
Brain Neoplasms
3
Astrocytoma
3
Adenocarcinoma, Follicular
3
Skin Neoplasms
2
Recurrence
2
Rectal Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neurofibroma, Plexiform
2
Leukemia, Myelomonocytic, Juvenile
2
Histiocytosis, Langerhans-Cell
2
Glioblastoma
2
Colonic Neoplasms
2
Advanced Solid Tumors
2
Uveal Melanoma
1
Interventions
Cyclophosphamide
8
Rituximab
5
fludarabine
4
Vincristine
4
Prednisone
4
Doxorubicin
4
fludarabine phosphate
3
Tacrolimus
3
Mycophenolic Acid
3
Etoposide
3
Busulfan
3
venetoclax
2
entrectinib
2
atezolizumab
2
alectinib
2
acalabrutinib
2
Whole-Body Irradiation
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mesna
2
Melphalan
2
Bortezomib
2
trametinib
1
pertuzumab
1
pembrolizumab
1
obinutuzumab
1
liposomal doxorubicin
1
isatuximab
1
ibrutinib
1
etoposide phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
trametinib
×
1 year
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled